Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Relapsed/Refractory or Older ALL
NCT03742323Phase 2Terminated
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Primary endpoints: Overall Response Rate at 6 months and Duration of Response at 6 months. Started Jul 2018; status: terminated.
02
Drugs
idelalisib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03742323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742323.